May 23, 2019 7:00am EDT Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
May 22, 2019 4:19pm EDT Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
May 21, 2019 4:15pm EDT Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
May 13, 2019 8:00am EDT Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
Apr 23, 2019 1:51pm EDT Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
Apr 22, 2019 7:00am EDT Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
Apr 4, 2019 7:30am EDT Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
